For Accredited Investors Only · Confidential · Not an Offer or Solicitation
Portfolio Construction

One Commitment. Four Portfolios.

A $250M target fund providing blended exposure across selective therapeutic innovation and a group of revenue-generating service and operating businesses, unified by a fund-wide AI strategy. Allocations, economics and underwriting detail are provided in the data room.

Selective Innovation

SP1 · Therapeutic Innovation

Milestone-driven equity in high-impact, longevity-focused cell and gene therapies with early signs of human efficacy, anchored by an investigational program and a staged pipeline pursuing defined proof milestones, licensing and strategic exits.

SP1 · Therapeutic Innovation

Staged, Evidence-Gated Equity

Capital is staged to verifiable proof points. The anchor is an investigational regenerative-medicine program (BioViva Neuro — investigational and not FDA approved), paired with additional innovation companies subject to diligence and defined evidence milestones. Value depends on scientific, regulatory, CMC and controlled-evidence outcomes.

Revenue & Services

Established Healthcare Operating Value

Operating businesses and capabilities that combine standalone economic potential with manufacturing, patient access, evidence and operating utility that can support portfolio execution and hedge innovation risk. A fund-wide AI strategy is applied across all portfolios.

SP2

ATMP Manufacturing & Supply Chain

Portfolio role

GMP-grade biofabrication services intended to help control therapy costs and secure supply.

Potential economics

Third-party services, equipment, consumables, licensing and strategic asset value.

SP3

Patient Access, Commercialization & Evidence

Portfolio role

Patient capture by medical concierge services directed toward an international providers network; curation of real-world outcomes data.

Potential economics

Service fees, licensing, royalties and JV economics where agreements provide.

SP4

Strategic Acquisitions

Portfolio role

Synergistic, profitable healthcare operators — recycling capital through leveraged transactions and increasing enterprise value through operating improvements.

Potential economics

Cash flow after business needs and debt service, debt paydown, recapitalization or sale.

Portfolio support may improve execution but does not guarantee revenue, clinical success, lower cost or realization. Unless expressly identified as closed, opportunities are prospective.

Sector Anchors

Anchor Assets Across the Ecosystem

Representative anchor relationships across innovation, manufacturing and patient capture. Letters of intent with BioViva and the Swiss CDMO are signed; neither transaction is closed.

Innovation

BioViva Neuro

Investigational hTERT + Klotho gene therapy for neurodegeneration. Controlled human evaluation is a key value milestone. Investigational and not FDA approved.

Manufacturing

Enable Biotech

GMP-grade, Swiss-based CDMO with expertise in manufacturing exosomes and cell and gene therapies.

Patient Capture

Longevity Concierge Group

Medical concierge with an international network of top providers specialized in regenerative medicine and science-based longevity.

BioViva CEO Liz Parrish is an Aether general partner, creating a related-party conflict that is managed and disclosed. Company names and relationships are subject to diligence and definitive documents and may change.

Proceeds to Investors

From Portfolio Value to LP Proceeds

Company value, Aether's economic interest, realized fund cash and LP distributions are distinct steps and should not be treated as interchangeable.

Company value→ Aether's interest→ Realized fund proceeds→ Fund economics→ LP distributions

Illustrative only. Realizations and distributions are not assured. Repaid or recycled principal is not additional profit. Modeled returns and fund terms are provided in the data room under NDA.

Request Access to the Data Room

Important information. Confidential discussion material for accredited investors only; not an offer or solicitation. Company names, allocations, valuations, timelines and economics are forward-looking, subject to diligence and definitive documents, and may change. Investigational programs are not FDA approved. Investments are illiquid and may result in total loss of capital.